Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.03.2024 | Case report

Nivolumab/triamcinolone

Subacute cutaneous lupus erythematosus and lack of efficacy

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Khorasanchi A, et al. Immune checkpoint inhibitor-induced subacute cutaneous lupus erythematosus: a case report and review of the literature. Frontiers in Medicine 11: Jan 2024. Available from: URL: https://dx.doi.org/10.3389/fmed.2024.1334718 Khorasanchi A, et al. Immune checkpoint inhibitor-induced subacute cutaneous lupus erythematosus: a case report and review of the literature. Frontiers in Medicine 11: Jan 2024. Available from: URL: https://​dx.​doi.​org/​10.​3389/​fmed.​2024.​1334718
Metadaten
Titel
Nivolumab/triamcinolone
Subacute cutaneous lupus erythematosus and lack of efficacy
Publikationsdatum
01.03.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-55310-4

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Multiple drugs

Case report

Multiple drugs

Case report

Tozinameran

Case report

Hydroxycarbamide

Case report

Insulin